← Leaderboards
Robert Paul Ricciardi
University Of Pennsylvania
$14,439,000
Attributed
$15,946,879
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,946,879 · 11
By mechanism
R42$5,022,725 · 2
U01$4,993,421 · 1
R01$3,939,632 · 3
R41$1,515,601 · 4
R21$475,500 · 1
Top collaborators
- Allen Bernard Reitz3 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Chandra M Sehgal$9,041,974
- Douglas Hamilton Smith$26,977,456
- Jayaram K Udupa$10,486,434
- Stuart N. Isaacs$9,020,266
- Helena Chang Chui$16,982,623
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralProteinsCellsAntiviral AgentsVirusIn VitroDna BiosynthesisInfectionMedicalLeadPreventPolymeraseAnalogMutantBaseSolubilitySafetyPharmaceutical ChemistryPharmaceutical PreparationsFuturePeptidesBindingToxic EffectPoxviridae
Grant awards (30)
Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum$967,415
R42 · FY2025 · AI · contact PI
Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum$1,039,551
R42 · FY2024 · AI · contact PI
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$975,748
R42 · FY2024 · AI
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$990,011
R42 · FY2023 · AI
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$1,050,000
R42 · FY2022 · AI
Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum$300,000
R41 · FY2022 · AI · contact PI
Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum$306,500
R41 · FY2021 · AI · contact PI
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$309,102
R41 · FY2020 · EY · contact PI
Discovering a Small Molecule that Targets the KSHV Processivity Factor for Treating Oral and Systemic Kaposi Sarcoma$300,000
R41 · FY2019 · DE · contact PI
DEVELOPMENT OF A NOVEL ANTIVIRAL TO TREAT AND PREVENT ACYCLOVIR RESISTANCE IN HUMAN OCULAR HERPES KERATITIS$299,999
R41 · FY2017 · EY · contact PI
Therapeutics that target processivity complex proteins of pox and other viruses$917,154
U01 · FY2013 · AI · contact PI
Therapeutics that target processivity complex proteins of pox and other viruses$975,696
U01 · FY2012 · AI · contact PI
Therapeutics that target processivity complex proteins of pox and other viruses$976,136
U01 · FY2011 · AI · contact PI
Therapeutics that target processivity complex proteins of pox and other viruses$985,959
U01 · FY2010 · AI · contact PI
Therapeutics that target processivity complex proteins of pox and other viruses$1,138,476
U01 · FY2009 · AI · contact PI
Targeting KSHV processivity to prevent oral KS in AIDS$297,267
R01 · FY2008 · DE · contact PI
Targeting KSHV processivity to prevent oral KS in AIDS$300,573
R01 · FY2007 · DE · contact PI
Organization and Expression of Adenovirus Genes$309,551
R01 · FY2006 · CA · contact PI
Targeting KSHV processivity to prevent oral KS in AIDS$309,551
R01 · FY2006 · DE · contact PI
Targeting KSHV processivity to prevent oral KS in AIDS$367,000
R01 · FY2005 · DE
Organization and Expression of Adenovirus Genes$317,000
R01 · FY2005 · CA
Organization and Expression of Adenovirus Genes$317,000
R01 · FY2004 · CA
Organization and Expression of Adenovirus Genes$317,000
R01 · FY2003 · CA
Discovery of antivirals against vaccinia and smallpox$237,750
R21 · FY2003 · AI
Organization and Expression of Adenovirus Genes$317,396
R01 · FY2002 · CA
Discovery of antivirals against vaccinia and smallpox$237,750
R21 · FY2002 · AI
ORGANIZATION AND EXPRESSION OF ADENOVIRUS GENES$299,678
R01 · FY2001 · CA
PF-8 AND POL-8 OF KSHV AS TARGETS OF VIRAL DNA SYNTHESIS$251,116
R01 · FY2001 · CA
ORGANIZATION AND EXPRESSION OF ADENOVIRUS GENES$292,019
R01 · FY2000 · CA
PF-8 AND POL-8 OF KSHV AS TARGETS OF VIRAL DNA SYNTHESIS$244,481
R01 · FY2000 · CA